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Abstract
Background: M. bovis Bacille Calmette-Gue ´rin (BCG), currently the only available vaccine against tuberculosis (TB), fails to
adequately protect individuals from active and latent TB infection. New vaccines are desperately needed to decrease the
worldwide burden of TB.
Methods and Findings: We created a recombinant strain of BCG that overproduces an L,D-transpeptidase in order to alter
the bacterial peptidoglycan layer and consequently increase the ability of this immunogen to protect against virulent M.
tuberculosis (Mtb). We demonstrate that this novel recombinant BCG protects mice against virulent Mtb at least as well as
control BCG, as measured by its ability to reduce bacterial burden in lungs and spleen, reduce lung histopathology, and
prolong survival. A nutrient starved recombinant BCG preparation, while offering comparable protection, elicited a response
characterized by elevated levels of select Th1 cytokines.
Conclusions: Recombinant BCG overexpressing a L,D-transpeptidase that is nutrient starved elicits a stronger Th1 type
response and is at least as protective as parent BCG. Results from this study suggest that nutrient starvation treatment of
live BCG vaccines should be further investigated as a way to increase host induction of Th-1 related cytokines in the
development of experimental anti-TB vaccines.
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Introduction
Tuberculosis (TB) still remains a major global health threat as
more lives were expected to be lost in 2009 than any previous year
in history [1]. In 2008, the latest year for which data is available
from the World Health Organization, there were ,9.4 million
incident cases of active TB around the world with 13–16% of these
patients being co-infected with HIV [2]. A major reason for the
high rate of active TB is reactivation from the vast reservoir of
latent infection into active disease. Latent TB describes a person
that harbors M. tuberculosis (Mtb) bacilli, the etiological pathogen of
TB, but is clinically asymptomatic [3]. An estimated 2 billion
humans are latently infected with Mtb [4], each with a 10%
likelihood of developing active TB during their lifetime [5]. Worse,
those patients co-morbid with HIV have been shown to carry an
increased risk of 10% likelihood of reactivation into active TB in a
year [6,7].
It is widely known that the intervention with the highest impact
on prevention of TB is a vaccine that can eliminate latent Mtb
infection. Although protective against childhood forms of
disseminated TB and TB meningitis, BCG vaccines are ineffective
against latent Mtb infection. One widely held view is that a vaccine
that more closely mimics the physiology of Mtb during latent
infection will elicit an effective immune response against these
bacilli and consequently may promote elimination of the infection.
An understanding of the physiological state of the Mtb during
latent infection is a prerequisite in order to identify antigens
specific to this state for development of a vaccine that can elicit
protection to prevent latent infection.
In vitro models designed to mimic the physiology of Mtb in the
dormant state are based on hypoxia, nutrient starvation, and
exposure to acid pH and nitric oxide as these conditions are
speculated to prevail in the lesion of latent infection [8,9,10,11,12].
A major drawback of this approach is that in vitro conditions often
mimic only a single aspect of a complex in vivo environment. Two
technical hurdles in studying latent Mtb infection in vivo are the low
number of bacilli, which is the quintessential aspect of this
infection, and the inability to reliably isolate these bacilli from
lungs of a host while preserving their physiological state.
Therefore, we have developed a nutrient starvation model to
isolate live vaccine bacilli in a dormant state and assess its ability to
protect the host against latent TB.
The molecular changes that govern the dormant state of Mtb
have yet to be fully characterized, but antigens specific to this state
have been reported [13,14] which have recently been shown to
induce immune responses specific to latent infection in humans
[15,16]. Expressing antigens associated with dormancy in a
recombinant BCG vaccine is a novel and promising strategy,
which we have considered in our study. It was shown that Mtb
remodels its peptidoglycan layer to predominantly contain 3R3
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phase of growth in vitro [17]. We showed previously that expression
of an L,D-transpeptidase, LdtMt2, which alters peptidoglycan cross
linkages, is increased during stationary phase, and is required for
survival during the chronic stage of growth in mice [18]. In an
excellent study, Clarke et al. show that murein fragments from the
peptidoglycan layer of bacteria prime the host immune system for
response against the pathogens through the Nod1 signaling
pathway [19]. These novel observations have led us to hypothesize
that overproduction of LdtMt2 in M. bovis BCG may render it
selectively more immunogenic against dormant bacilli in an Mtb
infection, specifically during the chronic phase, as this strain could
furnish murein that mimics the altered composition of peptido-
glycan layer in dormant Mtb.
We have created a recombinant strain of M. bovis BCG to
express an Mtb L,D-transpeptidase and profiled the immune
response elicited by this strain and the protection provided by it
against virulent Mtb using the mouse model of TB.
Although the mouse is not the perfect model of human TB, as
its granulomas do not caseate and cavitate (which are hallmarks of
the pathology of TB in humans), the mouse is the most widely used
model for vaccine studies [20], and it is an effective model of Mtb
growth in the lung and the mortality associated with it. As is
commonplace during the first phase of preclinical evaluation of
candidate anti-TB vaccines [20], this study was designed to detect
vaccine-attributable CFU reductions in the lungs of immunized
mice, as well as to determine the ability of the immunogen to
prolong life and protect the lungs from pathological signs of
disease. Equally important in the design of this study, is the
characterization of the host immune response both to the
immunizing agent, and subsequent virulent challenge. Over the
past decade, immunologists have detected striking similarities
between the human and mouse immune systems resulting in the
commercial production of an array of inexpensive, high quality
reagents and assays designed to detail the immune response [21] -
data which is important in assessing the immunogenic potential of
an anti-TB vaccine candidate [22] but is difficult to obtain and
expensive, if available at all for larger animal models.
Results
Recombinant BCG strain overexpressing LdtMt2
We created a recombinant BCG strain to overexpress LdtMt2
(Rv2518c). For this we used M. bovis BCG Copenhagen (Danish
strain 1331, BCG) as the host strain and transformed it with
pGS400H-2518, a Gateway destination plasmid derived from
pMV361 [23] into which ldtMt2 was cloned for expression from the
hsp60 promoter (Fig. S1). Although the host strain possesses an
orthologue of ldtMt2 we hypothesize, based on previous studies, that
an increase in the expression of this enzyme from an exogenous
copy of the gene will result in remodeling of the peptidoglycan
layer with extensive 3R3 transpeptide linkages that is character-
istic of Mtb in stationary phase [17] and thereby mimic the
constitution of peptidoglycan during latency. Peptidoglycan
fragments from bacteria are highly immunogenic and are
recognized by pattern recognition protein Nod1 and 2 [19]. The
genotypes of BCG transformants were verified by Southern
blotting: two of the tested recombinant strains were of the desired
genotype carrying a single copy of the plasmid at the attB site in
the bacterial chromosome (Fig. S2). Next, we isolated total RNA
from the recombinant BCG and the parent strain to verify the
levels of expression of ldtMt2. This analysis revealed that ldtMt2 was
expressed at ,58 fold higher levels in the recombinant strain
relative to the parent BCG strain. It is worth mentioning that we
could detect no in vitro growth defects in recombinant BCG (data
not shown). This strain is referred to as rBCG hereafter in the text.
In vivo growth of vaccine strains
We administered approximately 6 log10 CFU of BCG, rBCG,
or rBCG-NS intravenously to mice. As shown in Fig. 1, there was
minor variability in the numbers of implanted bacilli, as
determined by day +1 CFU counts from the spleen (Fig. 1B). It
is worth noting that after one day after immunization, there was
even less variation in number of bacilli recovered in the lung
(Fig. 1A). These data provided evidence that after culture in vitro,
rBCG delivered while in log phase or after nutrient starvation
exhibit no dissemination defects compared with the parental
strain. It has been shown that live BCG vaccine must replicate in
the host to be effective [24], therefore, we assessed the natural
growth of the vaccine strains over time before infecting the host
with virulent Mtb. The lungs and spleens of mice at predetermined
times before challenge were homogenized and diluted onto
commercial 7H11 Selective plates to recover viable bacilli. All
immunogens showed similar in vivo growth in both the lung and
the spleen (Fig. 1), and exhibited similar in vivo growth patterns
observed in comparable studies [25].
Protective effect and immunological response elicited by
rBCG
We evaluated the protective efficacy of rBCG by assessing the
following: (a) the extent to which it limited growth of virulent strain
of Mtb in the lungs and spleen of mice, (b) the extent of morbidity
based on histopathological observations of disease in the lungs,
and (c) the additional time (days) mice survived as a result of
Figure 1. In-vivo growth of immunogens. Growth of control BCG (triangle), rBCG (squares), and rBCG that has been nutrient starved in vitro
(rBCG-NS) (filled squares) in the lung (A) and the spleen (B) of C57/BL6 mice one day and 2, 4, and 6 weeks following immunization. Total CFU counts
from 3 mice per data point were log transformed and errors represent standard deviations of log transformed CFU counts.
doi:10.1371/journal.pone.0013773.g001
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elicited by rBCG by profiling 7 different TB-specific cytokines and
chemokines at different stages of immunization and subsequent
challenge. A hallmark of the BCG vaccine is its ability to elicit an
immune response which limits the growth of virulent Mtb and halts
the progression to active disease. At four weeks following
challenge, the time during which bacterial load peaks, the burden
of Mtb in the lungs (expressed in mean log10 bacilli per organ) was
7.5060.12, 5.8960.17, and 5.6960.09 in the lungs of naı ¨ve, BCG
and rBCG immunized mice respectively (Fig. 2A). A similar trend
in CFU reductions compared to naı ¨ve mice was observed at 8 and
16 weeks following challenge. This data demonstrated that our
experimental rBCG elicited an immune response that limited the
growth of Mtb in the lungs during all phases of infection at a
statistically significant level (p,0.001).
In a separate experiment to assess the ability of the immunizing
strain to prolong time to mortality following a high dose challenge
with the virulent strain, we observed 100% mortality of naı ¨ve mice
with median survival time of 120.5 days. In contrast, there were no
deaths or signs of mortality in mice immunized with rBCG
through 209 days after infection, at which time the experiment was
terminated, as per our design (Fig. 2B).
The decrease in bacterial burden in mice that received rBCG
correlated with a decrease in lung consolidation and number of
pathological lesions when compared to the group that did not
receive any immunization (Fig. 3). Histopathological observations
of lungs from all mice at two weeks post challenge revealed healthy
lung parenchyma. This was expected as recruitment of T-
lymphocytes and consequent cellular infiltration peaks after 2–3
weeks of infection in mice [26]. However, after eight weeks of
infection, cellular infiltration and consolidation of the lungs was
observed in naı ¨ve mice but was absent in lungs of rBCG
immunized and control mice.
Activation of the T-helper type 1 (Th1) response resulting in
robust cell mediated immunity plays a dominant role in combating
intracellular pathogens such as Mtb [26]. IL-12 has been shown to
direct the adaptive immune response to a Th1 type [27]. Two
weeks following challenge, the levels of IL-12 in the lungs of naı ¨ve
and rBCG immunized mice were 2606 pg/mL and 4797 pg/mL
respectively, however levels of this cytokine in these two groups of
mice were not different at later time points (Fig. 4A). IFN-c, the
major effector cytokine of the Th1 pathway, has been shown to be
Figure 2. Assessment of protection in immunized mice. (A)
Growth of virulent H37Rv in the lungs of mice that were immunized with
either control BCG (triangles), rBCG (squares), and rBCG that has been
nutrient starved in vitro (rBCG-NS) (filled squares) as assessed 1 day and
2, 4, 8, and 16 weeks after challenge. (B) Kaplan-Meier survival analysis
of naı ¨ve and immunized mice after challenge with a high dose of Mtb.
doi:10.1371/journal.pone.0013773.g002
Figure 3. Histopathology of lung tissue after challenge. Sectioned lung tissue from naı ¨ve and immunized mice taken 2 and 8 weeks after
virulent challenge (all panels 100x magnification, H&E stained).
doi:10.1371/journal.pone.0013773.g003
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Although IFN-c levels were similar during the acute stage
following challenge with Mtb, we observed significantly diminished
levels of IFN-c in rBCG immunized mice during the chronic stage
of infection compared to naı ¨ve mice (Fig. 4B). TNF-a is known to
act in concert with IFN-c to initiate production of reactive
nitrogen molecules resulting in an enhanced killing of Mtb within
macrophages [30]. Two weeks after challenge, we detected similar
levels of TNF-a in the lungs of naı ¨ve and rBCG-immunized mice.
However, during the chronic period of infection, TNF-a levels
were approximately 2-fold higher in the naı ¨ve mice possibly
reflecting an attempt by the host to limit proliferation of Mtb
(Fig. 4C).
Effects of in vitro nutrient starvation on protection
elicited by rBCG
One of our hypotheses is that bacilli isolated in a dormant state
from nutrient starved cultures mimic bacillary physiology during
latent infection and therefore can elicit an immune response that is
selective against latent TB. To test this hypothesis, mice were
immunized with a preparation of nutrient starved rBCG (referred
to as rBCG-NS hereafter), and its protective efficacy was assessed
by challenging mice with a virulent strain of Mtb. During the initial
phase of infection mice immunized with rBCG-NS inhibited
growth of virulent Mtb robustly. Considerably less CFU (0.69 log10
difference) of the virulent strain was observed in the lungs of
rBCG-NS immunized mice after 2 weeks of infection compared to
the control group of mice that received rBCG obtained at the log
phase of growth. Four weeks following challenge with virulent Mtb,
the burden of this strain in the lungs (expressed in log10 bacilli per
organ) was 7.5060.12, 5.6960.09, and 5.8860.12 per lung of
naı ¨ve, rBCG and rBCG-NS immunized mice respectively (Fig. 2A).
On and after 4 weeks of infection slight differences in mean
bacterial burden of the challenge strain were detected in rBCG-NS
and rBCG immunized, however these differences were not
statistically significant. We assessed lung histopathology in mice
immunized with rBCG-NS and observed less lung consolidation
and cellular infiltration compared to non-immunized control mice.
However, we were unable to detect qualitative differences in the
pathology from lungs of mice immunized with either rBCG-NS or
rBCG (Fig. 3).
We also evaluated the ability for rBCG-NS to elicit an immune
response to protect against death from an aerosol infection
intended to cause acute mortality. A time-to-death comparison
between mice immunized with nutrient starved and exponentially
grown rBCG revealed that although mice that received either
immunogen were significantly protected against death compared
to naı ¨ve controls, there were no deaths or morbidity in mice that
were immunized with either preparation of rBCG after 209 days
of infection when the experiment was terminated, as per our
design (Fig. 2B).
In order to quantify the measurable aspects of the immune
response in immunized animals, total levels of cytokines were
determined in the lungs of mice that received rBCG-NS. This
assessment revealed differences in the immune response elicited by
the experimental vaccines: approximately 60% more of the Th1
response inducing cytokine IL-12 was detected in the lungs of mice
immunized with rBCG-NS when assessed 2 weeks post challenge,
compared to mice that had received rBCG (Fig. 4A). At this stage,
we detected 7,666 pg and 4,797 pg of IL-12 in the lungs of mice
immunized with rBCG-NS, and rBCG respectively. Additionally,
higher levels of IFN-c were detected in the lungs of mice
immunized with rBCG-NS when assessed before challenge. One
day following immunization, we detected 89.65 pg and 18.17 pg
of IFN-c in the lungs of rBCG-NS and rBCG immunized mice
respectively (Fig. 5A). Similarly, just prior to challenge (6 weeks
post immunization) we detected 50.2 pg and 19.5 pg of IFN-c in
the lungs of rBCG-NS and rBCG immunized mice respectively.
Higher levels of TNF-a were detected one day following
immunization in the lungs of mice that received rBCG-NS: we
measured 537.8 pg and 146.4 pg of TNF-a in the lungs of rBCG-
NS and rBCG immunized mice respectively (Fig. 5B). An increase
in these Th1 cytokines provides evidence that mice immunized
with a nutrient starved preparation of rBCG were able to induce a
more pronounced immune response compared with mice that
were immunized with rBCG prepared from a culture at log phase
of growth.
Discussion
Several live attenuated vaccines have been engineered in an
attempt to reduce the worldwide TB burden. Efficacy of these
experimental vaccines has been evaluated preclinically
[31,32,33,34,35], or most recently in humans [36,37]. To our
knowledge only one vaccine candidate, AERAS-407, is designed
to target latent TB [38]. An ideal vaccine against latent TB would
elicit an immune response that specifically targets Mtb bacilli in all
organs and tissues during latent infection, and consequently would
induce the reduction or elimination of these bacilli. The major
reasons for a lack of a vaccine against latent TB are (a) very little is
known about the physiology and the antigenic profile of Mtb
during latent infection, and (b) the lack of a reliable model of
human TB latency. In vitro models that mimic a singular aspect of
bacillary physiology during latency have been developed and these
include nutrient starvation [10], oxygen depletion [9], nitric oxide
stress [11] and acid stress [8,12]. In this study we chose to use
Figure 4. Th1 cytokine induction post-challenge. Total levels (in pg/mL) of Th1 cytokines (A) IL-12, (B) IFN-c and (C) TNF-a measured in the
lungs of naı ¨ve, BCG, rBCG, or rBCG-NS immunized mice one day, and 6 weeks following immunization.
doi:10.1371/journal.pone.0013773.g004
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M. tuberculosis during latency.
We re-engineered BCG, the only vaccine currently in use
against TB, to over produce the transpeptidase LdtMt2 in an
attempt to create a strain whose peptidoglycan layer would closely
mimic that of bacilli during dormancy. It was recently reported
that expression of LdtMt2 is elevated during the non-replicating
stationary phase [18]. We hypothesized that this recombinant
BCG overexpressing ldtMt2 isolated after nutrient starvation stress
would illicit an immune response to specifically target bacilli in a
latent infection.
We evaluated the recombinant BCG constructed in this study in
mice and found that it protected mice at least as well as control
BCG in all measurements of protection performed in the study (i.e.
H37Rv CFU reduction, lung histopathology and delayed time-to-
death). While these results are encouraging, we had hypothesized
that our rBCG would be effective at inducing an immune reaction
that would target latent bacilli. Examination of lung and spleen
tissues at chronic phases of infection did not reveal significant
additional reductions in CFU or pathology by rBCG. Although
mice receiving rBCG were significantly protected from death
through the chronic phase of infection compared to naı ¨ve mice,
mortality rates were not significantly different in mice that received
control BCG.
Since it has been shown that Mtb possesses at least two active
L,D-transpeptidases that catalyze the formation of non-classical
linkages during the stationary phase of growth [17,18], there is the
possibility that overproduction of Rv2518c alone may be ineffective
at creating a strain which contains a sufficient amount of altered
peptidoglycan to induce protection against latent Mtb. In order to
address this possibility, we subjected rBCG to nutrient starvation in
vitro, and the resulting immunogen, rBCG-NS, was able to protect
mice as well as control BCG in all measures of protection assessed.
As observed in rBCG, however, we saw no signs that rBCG-NS
was able to protect mice better than control rBCG or control BCG
against populations of bacilli present during the chronic phase of
infection. However, when we examined the cytokine profile
elicited by rBCG-NS, we observed increases in lung IFN-c, and
TNF-a before challenge and higher levels of IL-12 after challenge
which indicates that rBCG-NS was able to elicit a stronger
immune response compared to rBCG. While not always indicative
of resulting protection [39], quantitative measurements of
cytokines is widely used to assess the ability of a vaccine to induce
an immune response.
Results from this study support using in vitro nutrient starvation
of a live BCG for a wide array of experimental vaccine studies in
order to increase Th1-mediated immunological effects. Experi-
mental vaccines using live recombinant BCG to express parasitic
or other key non-mycobacterial antigens which may preferentially
promote a T-helper type 2 (Th2) cell mediated response could
benefit from in vitro nutrient starvation to induce a more preferable
balance between Th1 and Th2 responses to help alleviate
unfavorable Th2 induced asthmatic responses [40]. Likewise, a
BCG that induces a stronger Th1 response could potentially
increase the inherently positive anti-allergen effects of currently
available BCG vaccines [41]. Additionally, studies that involve
coadministration of a live rBCG and an adjuvanted subunit
vaccine [42] could benefit by increasing the Th1:Th2 balance of
the cell mediated immune response potentially offering greater
flexibility in choosing an effective adjuvant, often a difficult topic
for vaccinologists due to several factors [20]. Finally, one
shortcoming of live BCG vaccines is that they have been shown
to fail to protect individuals against TB in regions that contain a
high burden of TB disease [43] potentially due to the increased
presence of environmental mycobacteria in these countries [44]. A
BCG vaccine that is able to induce a more robust cell mediated
response characterized by higher induction of IFN-c and IL-12
could potentially alleviate the ‘‘blocking’’ hypothesis presented in
[44], especially in regions that administer BCG after potential
exposure to mycobacteria through the water or soil can occur (e.g.
after a newborn has left the hospital). It is clear from this study that
further experiments are needed to determine whether increased
host induction of Th1 cytokine resulting from in vitro nutrient
starvation of rBCG is due to the overexpression of the LdtMt2,o r
whether this effect can be recapitulated in wild type BCG.
Although data from experiments using the exponentially grown
rBCG do not necessarily support moving forward with this strain
in more rigorous testing at this time, experiments to further
characterize the effects of in vitro nutrient starvation on rBCG and
the parental wild-type BCG should be pursued. This rBCG-NS,
while able to protect mice as well as the relevant controls, and
elicited a stronger immune response in mice marked by higher
levels of lung IFN-c, TNF-a, and IL-12 compared to the parent
strain that was grown exponentially. A more robust response in
these cytokines offer researchers a useful tool to incorporate
customized Th1 responses in studies using live BCG to express
heterologous antigens, in studies involving use of adjuvants, and
could possibly even help increase resulting protection in BCG
immunized populations that do not respond effectively to current
BCG.
Materials and Methods
Ethics statement
No ethics statement is required for this study. All animal
protocols used in this study have been reviewed and approved by
Figure 5. Th1 cytokine induction pre-challenge. Total levels (in pg/mL) of Th1 cytokines (A) IFN-c and (B) TNF-a measured in the lungs of BCG,
rBCG, or rBCG-NS immunized mice one day, and 6 weeks following immunization.
doi:10.1371/journal.pone.0013773.g005
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(protocol number MO09M101).
Bacterial strains and in vitro growth conditions
M. bovis BCG Copenhagen (Danish strain 1331) was purchased
from ATCC (Manassas, VA). H37Rv was used as the virulent Mtb
strain for challenge studies. Mycobacterial cultures were grown in
Middlebrook 7H9 broth (Difco) supplemented with 0.5% glycerol,
10 mg/mL cycloheximide (Sigma), 0.05% Tween-80 (Sigma), and
10% BBL Middlebrook OADC enrichment (Beckton Dickinson).
For colony forming unit (CFU) determination, bacilli were grown
on Middlebrook 7H10 agar (Difco) supplemented with 0.5%
Glycerol, 10 mg/mL cycloheximide (Sigma), 0.05% Tween-80
(Sigma), and 10% BBL Middlebrook OADC enrichment (Beckton
Dickinson). OmniMAX 2 -T1
R E. coli (Invitrogen) was used in all
DNA cloning procedures and was grown according to the
manufacturer’s directions.
Plasmid and strain construction
Reagents for DNA cloning procedures were used according to
the manufacturers’ supplied protocols or as described [45]. The
1,227 base pair ldtMt2 was cloned from Mtb genomic DNA (obtained
through the TB Vaccine Testing and Research Materials Contract,
Colorado State University) via polymerase chain reaction with
primers GW-Rv2518c@1-SP (59- GGGGACAAGTTTGTA-
CAAAAAAGCAGGCTAGGAGGGAAGGCATGCCAAAGG-
TGGGGATTG -39) and GW-Rv2518c@1227-ASP (59- GG-
GGACCACTTTGTACAAGAAAGCTGGGTTTACGCCTTG-
GCGTTA CCG G -39). The resulting amplicon was purified and
recombined into the Gateway entry vector pDONR/Zeo (Invitro-
gen). The ldtMt2 coding sequence was fully sequenced (Genewiz),
compared to the published sequence in GenBank (http://www.
ncbi.nlm.nih.gov/Genbank) and a verified clone with the correct
sequence was transferred into the mycobacterial – E. coli Gateway
shuttle vector pGS400H [46]. The resulting plasmid was electro-
porated into BCG using standard techniques [47]. Selection of
transformants was performed on Middlebrook 7H10 agar in the
presence of 50 mg/mL hygromycin at 37uC for 3–4 weeks.
Candidates were subcultured and verified using Southern analysis
and multiple vials of positive clones were frozen in 15% glycerol at
280uC.
Measurement of antigen expression
Approximately 1 mg of total RNA isolated from an in vitro
culture of the recombinant strain at the late exponential phase of
growth (A600 nm=1.2) was treated with TURBO DNase (Ambion)
and reverse transcribed into cDNA with random hexamers using
the SuperScript First-Strand Synthesis System for RT-PCR
(Invitrogen) using the manufacturer’s supplied protocol. Real-time
detection of ldtMt2 transcripts was performed using iQ SYBR-
Green Supermix (Bio-Rad) with the primers Rv2518c-RT1
(AGCACATCATCATGGACTCG), and Rv2518c-RT2 (CGCT-
TGACATGGTCGTAGAA) in an iCycler iQ Real-Time PCR
Detection System (Bio-Rad). Transcript levels of ldtMt2
(BCG_2539c) in the parent and the recombinant strain were
normalized to sigA and fold change in expression level was
calculated using the comparative Ct method [48].
Experimental animals
C57/BL6 mice (Charles River Laboratories) were housed in the
pathogen-free biosafety level 3 vivarium facility at Johns Hopkins
University. Mice were provided food and water ad libitum as well as
appropriate monitoring and clinical care. All protocols used in this
study have been reviewed and approved by the Johns Hopkins
Institutional Animal Care and Use Committee (protocol number
MO09M101).
Preparation of immunizing agents and immunizations
Table S1 lists the immunogens used in this study. Twenty eight
mice per group were immunized in the lateral tail vein by
inoculating 0.2 ml of a suspension containing approximately
1610
7 CFU of either control BCG, the recombinant strain
(rBCG) or rBCG that was nutrient starved (rBCG-NS). The
negative control group of 20 mice did not receive any
immunization. BCG and rBCG preparations were made by
growing respective strains in 7H9 broth to log phase and diluting
to a density of ,5610
7 CFU/mL using phosphate buffered saline
(PBS). To prepare rBCG-NS, we grew rBCG in 7H9 broth to log
phase, washed twice with PBS containing 0.05% Tween-80
(PBST) then diluted into PBST to a concentration of approx-
imately 5610
7 CFU/mL and incubated at 37uC as a standing
culture for 1 week. Diluted samples of all suspensions used for
immunization were plated onto 7H10 agar to enumerate viable
bacilli. At 1 day and 2, 4, and 6 weeks post immunization, the
lungs and spleens of vaccinated animals were removed, homog-
enized and plated onto 7H11 Selective agar in order to assess the
in vivo growth of the immunizing strains prior to challenge.
Challenge with virulent M. tuberculosis
All mice were challenged in a Glas-col Middlebrook Inhalation
Exposure System (Glas-col Inc.) with a suspension of Mtb H37Rv at
6 weeks following immunization. A log phase culture of H37Rv
was used to implant ,3 log10 bacilli in the lungs of mice for
assessment of growth of the challenge strain. A separate infection
was carried out to implant ,4 log10 CFU of H37Rv: this is a high
dose that results in death of naı ¨ve mice and is therefore suitable for
measuring protection against virulent Mtb. For this assessment, 10
mice from each group that received immunization and 13 mice for
the naı ¨ve group were used. Diluted samples of all suspensions used
for aerosol infection were plated onto 7H10 agar to determine
infective dose. Implantation rates were determined by plating lung
homogenates from naı ¨ve mice obtained one day after aerosol
challenge onto 7H11 Selective agar plates.
Determination of bacterial burden and histopathology
Lungs and spleens of 3 mice per time point were aseptically
removed and transferred to a 2 ml screw cap tube containing
2 mm glass beads and homogenized using a Biospec Mini Bead
Beater (BioSpec Products) in a total volume of 1 mL of PBS. In
order to measure the bacterial burden of the challenge strain in
immunized animals, diluted organ homogenates were plated onto
Middlebrook 7H11 Selective plates containing 2 mg/mL 2-
thiophenecarboxylic acid (Sigma). Total CFU counts were
determined following 3–4 weeks of incubation at 37uC. For
histopathological studies, lung tissue samples were obtained from
mice at 2, 8, and 16 weeks post challenge, fixed in formalin,
paraffin imbedded, sectioned and stained with hematoxylin and
eosin. Slides were examined using a Nikon Eclipse E8000
microscope outfitted with a Nikon DXM1200 camera and Nikon
ACT-1 image acquisition software.
Cytokine measurements
Lung homogenates in a total volume of 1 mL from sacrificed
animals at predetermined times after immunization or subsequent
challenge were thawed, diluted 5-fold in PBS, filtered using a 0.22
um syringe filter (Millipore) and assessed using a Bio-Plex Express
Recombinant BCG Vaccine
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performed using a Bio-Plex 200 System (Bio-Rad) and total lung
levels of IL-1b, IL-10, IL-12 (p40), IFN-g, MIP-1a, RANTES, and
TNF-a were measured.
Statistical analysis
The two-tailed Student’s t-test was performed to determine
significance in CFU measurements. Log-rank test analysis was
used to compare survival data using PRISM (Graphpad Software).
P values #0.05 were used to indicate significant differences.
Supporting Information
Table S1 List and description of immunogens used in this study.
Found at: doi:10.1371/journal.pone.0013773.s001 (0.03 MB
DOC)
Figure S1 Plasmid map of pGS400H-2518. The E. coli/Mtb
shuttle plasmid pGS400H is a Gateway-enabled derivative of
pMV361 which accepts fragments from Gateway entry plasmids
and features expression of the exogenous gene from the
constitutively strong hsp60 promoter region of mycobacteria. This
plasmid integrates stably into the mycobacterial genome at the
attB locus using the plasmid-encoded mycobacteriophage L5
integrase, and features hygromycin resistance for selection of
transformants.
Found at: doi:10.1371/journal.pone.0013773.s002 (1.19 MB TIF)
Figure S2 Southern blot data used to verify the correct genotype
of rBCG transformants. (A) Genomic DNA from the parental
BCG strain (Lane 2) and putative rBCG transformants (Lanes 3–
12) were digested with XhoI, run on a 0.8% agarose gel
transferred to a nylon membrane and hybridized to a DIG-
labelled probe homologous to a fragment of Mtb gene Rv2518c.
Lane 1 contains commercial Dig labeled molecular weight
markers and the fragment sizes are denoted. The expected
fragment size for the parental strain, 3 kilobases was observed in
lane 2. Lanes 11 and 12, among others, display the correct
fragment sizes for rBCG which is 3 kilobases (the wild-type copy)
and 10 kilobases (the exogenous copy). (B) The nylon membrane
from (A) was stripped using the manufacturers supplied protocol
and hybridized to a DIG-labeled probe homologous to a fragment
of the Hygromycin resistance gene present on pGS400H-2518.
Lane 1 contains commercial Dig labeled molecular weight
markers and the fragment sizes are denoted. There should be no
fragment expected for the parental strain, as was observed in lane
2. Lanes 11 and 12, display the correct fragment sizes for rBCG
which is 10 kilobases.
Found at: doi:10.1371/journal.pone.0013773.s003 (5.39 MB TIF)
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